BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3117086)

  • 1. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
    Halila H; Huhtala ML; Haglund C; Nordling S; Stenman UH
    Br J Cancer; 1987 Aug; 56(2):153-6. PubMed ID: 3117086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
    de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
    Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
    Halila H; Lehtovirta P; Stenman UH
    Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
    Mogensen O; Mogensen B; Jakobsen A
    Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
    Wu JT; Miya T; Knight JA; Knight DP
    Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
    Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
    Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncofetal antigens in ovarian cyst fluids.
    Kraly DH; Koh SH; Hay DL; Cauchi MN
    Gynecol Obstet Invest; 1984; 18(3):117-21. PubMed ID: 6208091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: diagnostic adjunct to cytology.
    Pinto MM; Bernstein LH; Brogan DA; Parikh F; Lavy G
    Diagn Cytopathol; 1990; 6(3):160-3. PubMed ID: 1696873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma.
    Lewandrowski KB; Southern JF; Pins MR; Compton CC; Warshaw AL
    Ann Surg; 1993 Jan; 217(1):41-7. PubMed ID: 8424699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
    Stenman UH
    Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions.
    Räty S; Sand J; Alfthan H; Haglund C; Nordback I
    J Gastrointest Surg; 2004; 8(5):569-74. PubMed ID: 15239993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of gynaecologic tumour markers.
    Halila H; Alfthan H; Stenman UH
    Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of mucin-like carcinoma-associated antigen in the cyst fluid differentiates mucinous from nonmucinous pancreatic cysts.
    Sperti C; Pasquali C; Pedrazzoli S; Guolo P; Liessi G
    Am J Gastroenterol; 1997 Apr; 92(4):672-5. PubMed ID: 9128321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology.
    Gadducci A; Ferdeghini M; Facchini V; Ceccarini T; Prontera C; Bianchi R; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(2):111-5. PubMed ID: 2379509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
    Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of cyst puncture in the differential diagnosis of benign ovarian tumours.
    Vercellini P; Oldani S; Felicetta I; Bramante T; Rognoni MT; Crosignani PG
    Hum Reprod; 1995 Jun; 10(6):1465-9. PubMed ID: 7593516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
    Leminen A
    Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2.
    Koivunen E; Itkonen O; Halila H; Stenman UH
    Cancer Res; 1990 Apr; 50(8):2375-8. PubMed ID: 2180568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.